Xeris Pharmaceuticals Inc (XERS NASDAQ) stock market data APIs
$5.6503
-0.03(-0.5%)
as of March 27, 2025
Xeris Pharmaceuticals Inc Financial Data Overview
Xeris Biopharma Holdings, Inc., engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Prev. Close
5.6774
Open
5.6503
High
5.8018
Low
5.6352
52 wk Range
1.69-6.07
Market Cap
904 M
Shares Outstanding
154 M
Revenue
203 M
EPS
-0.03
Beta
1.208
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Xeris Pharmaceuticals Inc data using free add-ons & libraries
Get Xeris Pharmaceuticals Inc Fundamental Data
Xeris Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 203 M
- EBITDA: -15 476 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-04
- EPS/Forecast: -0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xeris Pharmaceuticals Inc News
New
Prem Watsa's Strategic Moves: CVS Health Corp Takes Center Stage with 7.82% Portfolio Share
Insightful Analysis of Prem Watsa (Trades, Portfolio)'s Fourth Quarter 2024 13F Filing Prem Watsa (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2024, providing insig...
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
2023 was dominated by the Magnificent Seven stocks, which has left investors wondering how much higher mega-cap stocks can go. Investors worry that growth is nearing a peak or perhaps reversing. That ...
11 High Growth Micro-Cap Stocks to Buy
In this article, we discuss 11 high-growth micro-cap stocks to buy. To skip the detailed analysis and past performance of micro-cap stocks, go directly to the 5 High Growth Micro-cap Stocks to Buy. S...
10 Best Fast Growing Penny Stocks to Buy Now
In this article, we will take a look at the 10 best fast growing penny stocks to buy now. To see more such companies, go directly to 5 Best Fast Growing Penny Stocks to Buy Now. The second half of 20...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
